Clinical Trials on Headache Disorders, Primary in Japan

Total 2902 results

Otsuka Pharmaceutical Co., Ltd.

Recruiting

Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use

Migraine Disorders

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients

Migraine

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine

Migraine

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine

Migraine

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine

Migraine

Japan
GlaxoSmithKline

Completed

Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Cluster Headache In Japan

Migraine Disorders

Japan
GlaxoSmithKline

Completed

Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents

Migraine Disorders

Japan
Eli Lilly and Company

Completed

A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine

Migraine

United States, Puerto Rico, Japan
Janssen Pharmaceutical K.K.

Completed

Continuous Treatment Study of Topiramate in Migraine Participants

Migraine

Japan
Janssen Pharmaceutical K.K.

Completed

A Dose-Finding Study of Topiramate (JNS019) in Participants With Migraine

Migraine

Japan
Eli Lilly and Company

Completed

A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine

Migraine

Japan
H. Lundbeck A/S

Active, not recruiting

Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan

Migraine

Japan
Eli Lilly and Company

Completed

A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine

Migraine

Japan
Eli Lilly and Company

Completed

A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine (MONONOFU)

Migraine

Japan
H. Lundbeck A/S

Completed

Eptinezumab in Participants With Episodic Cluster Headache (ALLEVIATE)

Cluster Headache, Episodic

Spain, United States, Germany, Portugal, Italy, Netherlands, Finland, Belgium, Czechia, Denmark, France, Georgia, Russian Federation, United Kingdom, Greece, Estonia, Japan, Norway, Sweden
Amgen

Completed

A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention

Migraine

Japan
Amgen

Completed

A Controlled Trial of Erenumab in Migraine Prevention

Migraine

Japan
AbbVie

Recruiting

Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine (Release)

Migraine

Japan
Pfizer

Active, not recruiting

Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)

Migraine

Japan
H. Lundbeck A/S

Recruiting

Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine (Sunrise)

Migraine

Poland, China, Spain, Georgia, Japan, Korea, Republic of, Taiwan, Slovakia
AbbVie

Active, not recruiting

A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine

Chronic Migraine | Episodic Migraine

Japan
Eli Lilly and Company

Completed

A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine (CONQUER)

Migraine

Korea, Republic of, United States, Spain, Germany, Canada, United Kingdom, Czechia, Netherlands, Puerto Rico, Belgium, Japan, France, Hungary
AbbVie

Enrolling by invitation

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine

Episodic Migraine

United States, Canada, Denmark, Hungary, Italy, Poland, Puerto Rico, Spain, United Kingdom, Israel, Japan, Sweden
Amgen
Novartis

Recruiting

Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine (OASIS(EM))

Migraine

United States, Spain, Japan, Poland, Belgium, Canada, United Kingdom, Germany, Hungary, Italy, Colombia, Russian Federation, Portugal, Switzerland, Finland, Puerto Rico
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine

Migraine

United States, Canada, Czechia, Finland, Israel, Japan, Poland, Russian Federation, Spain
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine (HALO)

Migraine

United States, Canada, Czechia, Finland, Israel, Japan, Poland, Russian Federation, Spain
AbbVie

Recruiting

Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine (ECLIPSE)

Migraine

United Kingdom, Belgium, China, Czechia, Germany, Italy, Japan, Korea, Republic of, Poland, Portugal, Slovakia, Spain, Sweden, Taiwan
Eli Lilly and Company

Recruiting

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine (REBUILD-1)

Episodic Migraine

United States, Spain, India, Mexico, Japan, Netherlands, Puerto Rico, Denmark, Italy, Germany
Pfizer

Completed

Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)

Migraine

Japan
AbbVie

Recruiting

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine (Kaleidoscope)

Episodic Migraine

United States, Puerto Rico, Spain, Canada, Netherlands, Israel, Sweden, Poland, Hungary, France, Denmark, Japan, United Kingdom, Italy, Romania, Belgium
Amgen
Novartis

Recruiting

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine (OASIS(CM))

Migraine

United States, Japan, Belgium, Canada, United Kingdom, Germany, Poland, Hungary, Italy, Colombia, Russian Federation, Finland, Puerto Rico
Pfizer
Biohaven Pharmaceutical Holding Company Ltd.

Recruiting

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Migraine

United States, France, Spain, Poland, Japan, Canada, Italy
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

Migraine

United States, Canada, Czechia, Finland, Israel, Japan, Poland, Russian Federation, Spain
Eli Lilly and Company

Recruiting

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine (REBUILD-2)

Chronic Migraine

United States, Spain, India, Mexico, France, Japan, Netherlands, Puerto Rico, Denmark, Italy, Germany
Eli Lilly and Company

Recruiting

A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1)

Migraine

United States, Spain, Italy, Mexico, India, Belgium, Japan, Netherlands, Puerto Rico, Germany, Romania, United Kingdom, France, Russian Federation
Eli Lilly and Company

Recruiting

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

Migraine

United States, Spain, Italy, India, Mexico, Belgium, Japan, Netherlands, Puerto Rico, Germany, Romania, United Kingdom, France, Russian Federation
Allergan

Completed

Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

Chronic Migraine

United States, Australia, Canada, China, Czechia, Denmark, France, Germany, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Spain, Sweden, Taiwan, United Kingdom
Pfizer

Recruiting

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Pediatric Migraine

United States, Spain, Canada, China, Poland, United Kingdom, Mexico, Japan, Sweden
Taiho Pharmaceutical Co., Ltd.

Completed

Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence

Stress Urinary Incontinence

Japan
Taiho Pharmaceutical Co., Ltd.

Completed

A Study of TAS-303 in Female Patients With Stress Urinary Incontinence

Stress Urinary Incontinence

Japan
Translational Research Center for Medical Innovation...
Shinshu University Hospital

Completed

Female Patients With Signs of uRgE and Stress Urinary Incontinence Study of Propiverine Hydrochloride (FRESH)

Urinary Incontinence

Japan
Osaka City University

Completed

Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder (OCDDRUG)

SSRI-Refractory Obsessive-Compulsive Disorder

Japan
Mochida Pharmaceutical Company, Ltd.
Pfizer

Completed

A Study of MD-120 in Patients With Depression

Major Depressive Disorder

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2 Trial of OPC-64005 for Major Depressive Disorder

Major Depressive Disorder

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study of Brexpiprazole in Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Taiho Pharmaceutical Co., Ltd.

Completed

A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence

Stress Urinary Incontinence

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism

Autism

Japan
Astellas Pharma Inc

Completed

Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Otsuka Pharmaceutical Co., Ltd.

Active, not recruiting

Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)

Bipolar Disorder I

Japan

Clinical Trials on Headache Disorders, Primary in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations